IDR 400.0
(-1.48%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 100.18 Billion IDR | 23.34% |
2022 | 81.22 Billion IDR | -11.78% |
2021 | 92.07 Billion IDR | 120.41% |
2020 | 41.77 Billion IDR | 158.01% |
2019 | 16.19 Billion IDR | 25.29% |
2018 | 12.92 Billion IDR | 58.75% |
2017 | 8.14 Billion IDR | 416.0% |
2016 | 1.57 Billion IDR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q3 | 28.8 Billion IDR | 15.48% |
2024 Q1 | 19.11 Billion IDR | -68.28% |
2024 Q2 | 26.79 Billion IDR | 40.18% |
2023 Q2 | 18 Billion IDR | 50.23% |
2023 FY | 100.18 Billion IDR | 23.34% |
2023 Q3 | 13.36 Billion IDR | -25.72% |
2023 Q4 | 60.25 Billion IDR | 350.69% |
2023 Q1 | 11.98 Billion IDR | -66.51% |
2022 FY | 81.22 Billion IDR | -11.78% |
2022 Q4 | 35.78 Billion IDR | 130.68% |
2022 Q3 | 15.51 Billion IDR | 5.9% |
2022 Q2 | 14.64 Billion IDR | -4.21% |
2022 Q1 | 15.29 Billion IDR | -28.91% |
2021 Q1 | 12.37 Billion IDR | -55.74% |
2021 FY | 92.07 Billion IDR | 120.41% |
2021 Q4 | 21.51 Billion IDR | -36.15% |
2021 Q3 | 33.68 Billion IDR | 37.49% |
2021 Q2 | 24.5 Billion IDR | 98.06% |
2020 Q2 | 4 Billion IDR | -4.63% |
2020 Q1 | 4.19 Billion IDR | 48.79% |
2020 FY | 41.77 Billion IDR | 158.01% |
2020 Q4 | 27.94 Billion IDR | 397.07% |
2020 Q3 | 5.62 Billion IDR | 40.44% |
2019 Q2 | 3.94 Billion IDR | 51.27% |
2019 FY | 16.19 Billion IDR | 25.29% |
2019 Q1 | 2.6 Billion IDR | 0.0% |
2019 Q3 | 6.81 Billion IDR | 72.95% |
2019 Q4 | 2.82 Billion IDR | -58.62% |
2018 Q1 | 3.07 Billion IDR | 0.0% |
2018 FY | 12.92 Billion IDR | 58.75% |
2017 FY | 8.14 Billion IDR | 416.0% |
2016 FY | 1.57 Billion IDR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
PT Enseval Putera Megatrading Tbk. | 1992.05 Billion IDR | 94.971% |
PT Kimia Farma (Persero) Tbk | 4350.51 Billion IDR | 97.697% |
PT Millennium Pharmacon International Tbk | 184.42 Billion IDR | 45.675% |
PT Soho Global Health Tbk | 851.38 Billion IDR | 88.233% |